2023-504324-26-00招募中1 期
Randomized, Double Blind, Placebo Controlled "first-in-human" Study to Assess the Safety and Tolerability of Single Ascending Intravenous Doses and Multiple Intravenous Doses of RA0127 in Healthy Young Volunteers
Remab Therapeutics S.L.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年6月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Rafael Mañez Mendiluce
Scientific
Remab Therapeutics S.L.
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, Hospitalized Patients, Study to Assess Efficacy and Safety of HP-3070 in Subjects with SchizophreniaSchizophreniaEUCTR2015-005134-21-SKoven Pharmaceuticals, Inc.617
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled, Fixed Dose-Ranging Study to Assess the Safety, Tolerability, and Efficacy of Topiramate Oral Liquid and Sprinkle Formulations as an Adjunct to Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months of Age, Inclusive) With Refractory Partial-Onset Seizures, With Open-Label ExtensioAdjunct to Concurrent Anticonvulsant Therapy for Infants (1 to 23 Months of Age, Inclusive) With Refractory Partial-Onset SeizuresMedDRA version: 6.1Level: PTClassification code 10010145EUCTR2005-001338-33-ITJANSSEN-CILAG240
进行中（未招募）
不适用
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF) within 12 hours after hospital admission (Pulmonary Artery Catheter eg, Swan-Ganz not required) - COMPOSE EARLYAcute Decompensated Chronic Congestive Heart Failure (ADHF)MedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureEUCTR2009-017082-39-GBBayer Healthcare AG, D-51368, Leverkusen160
进行中（未招募）
不适用
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 µg/h, 100 µg/h, 150 µg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF) within 12 hours after hospital admission (Pulmonary Artery Catheter eg, Swan-Ganz not required. - COMPOSE EARLYAcute Decompensated Chronic Congestive Heart Failure (ADHF)MedDRA version: 12.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureEUCTR2009-017082-39-ITBayer HealthCare AG160
进行中（未招募）
不适用
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects with Acute Decompensated Chronic Congestive Heart Failure (ADHF)Acute Decompensated Chronic Congestive Heart Failure (ADHF)MedDRA version: 9.1Level: LLTClassification code 10064653Term: Acute decompensated heart failureEUCTR2009-014377-40-SEBayer Healthcare AG100